BCAL Diagnostics secures key accreditation

BCAL Diagnostics (ASX:BDX) has announced that its laboratory in North Ryde, Sydney, has received accreditation from the National Association of Testing Authorities Australia (NATA). This important milestone certifies that the laboratory meets high standards, facilitating the commercialisation of BCAL's BREASTEST®, a blood test for breast cancer detection.

BCAL Diagnostics strategic outlook

BCAL Diagnostics has achieved a significant milestone with the NATA accreditation of its Sydney laboratory. This accreditation ensures compliance with rigorous standards, paving the way for the commercialisation of the BREASTEST®, a blood test for early breast cancer detection. BCAL is finalizing validation procedures and aims to launch the test in collaboration with the Sydney Breast Clinic, complementing mammography. The company, founded in 2010, is committed to enhancing early breast cancer diagnosis and improving patient outcomes globally. With millions of new cases annually, BCAL aims to make its screening tools widely accessible, impacting patient outcomes positively.

Executive insights on accreditation

The NATA accreditation demonstrates that the laboratory's quality systems and processes meet international and Australian standards.' 'The accreditation brings BCAL closer to providing innovative technology for improved health outcomes in breast cancer screening.